Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study by Lackner, Peter et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Malaria Journal
Open Access Research
Glatiramer acetate reduces the risk for experimental cerebral 
malaria: a pilot study
Peter Lackner*, Andrea Part, Christoph Burger, Anelia Dietmann, 
Gregor Broessner, Raimund Helbok, Markus Reindl, Erich Schmutzhard and 
Ronny Beer
Address: Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
Email: Peter Lackner* - peter.lackner@i-med.ac.at; Andrea Part - andreareisinger@hotmail.com; Christoph Burger - c.burger@salk.at; 
Anelia Dietmann - anelia.dietmann@i-med.ac.at; Gregor Broessner - gregor.broessner@i-med.ac.at; Raimund Helbok - raimund.helbok@uki.at; 
Markus Reindl - markus.reindl@i-med.ac.at; Erich Schmutzhard - erich.schmutzhard@i-med.ac.at; Ronny Beer - ronny.beer@i-med.ac.at
* Corresponding author    
Abstract
Background: Cerebral malaria (CM) is associated with high mortality and morbidity caused by a
high rate of transient or persistent neurological sequelae. Studies on immunomodulatory and
neuroprotective drugs as ancillary treatment in murine CM indicate promising potential. The
current study was conducted to evaluate the efficacy of glatiramer acetate (GA), an
immunomodulatory drug approved for the treatment of relapsing remitting multiple sclerosis, in
preventing the death of C57Bl/6J mice infected with Plasmodium berghei ANKA.
Methods and Results: GA treatment led to a statistically significant lower risk for developing CM
(57.7% versus 84.6%) in treated animals. The drug had no effect on the course of parasitaemia. The
mechanism of action seems to be an immunomodulatory effect since lower IFN-gamma levels were
observed in treated animals in the early course of the disease (day 4 post-infection) which also led
to a lower number of brain sequestered leukocytes in treated animals. No direct neuro-protective
effect such as an inhibition of apoptosis or reduction of micro-bleedings in the brain was found.
Conclusion: These findings support the important role of the host immune response in the
pathophysiology of murine CM and might lead to the development of new adjunctive treatment
strategies.
Background
A major cause of morbidity and mortality of Plasmodium
falciparum malaria is cerebral malaria (CM). It presents as
a diffuse encephalopathy with alteration of conscious-
ness, ranging from drowsiness to deep coma and is fre-
quently accompanied by seizures [1]. Mortality is high
and neurological sequelae are observed in approximately
10% of the survivors [2]. The pathophysiological mecha-
nisms of CM are yet not fully understood. Most research-
ers agree that the immune response of the host is a critical
factor in the pathogenesis of CM. Different aspects have
been studied and in particular pro-inflammatory
cytokines and activated T-lymphocytes have been shown
to be related to the development of CM [3-5]. Impor-
tantly, recent studies suggest a critical role of interferon-
responsive mechanisms in murine and human CM [6,7].
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Therefore, immunomodulatory drugs have been consid-
ered as potential adjunctive treatment regimens for severe
malaria. Despite beneficial effects in the mouse model
[8,9], corticosteroids have been shown to be ineffective or
even deleterious in human CM [10,11]. Similar findings
were observed with TNF-alpha antagonists. While TNF-
alpha blockage reduces the rate of CM in mice, the data
from human trials are far from clear [12-14]. In rodents
positive effects were achieved with thalidomide, a potent
inhibitor of TNF-alpha and inductor of a Th2-based
immune response [15,16]. Recent studies implicate, that
the potent immunosuppressive agent cyclosporin A may
inhibit parasite development [17] and decrease neurolog-
ical complications in Plasmodium berghei infected mice,
when applied in low dose [18]. The neuropathological
alterations in murine CM resemble in some aspects the
neuro-inflammatory response seen in experimental aller-
gic encephalitis (EAE), an animal model for multiple scle-
rosis [19,20]. Therefore the current study was designed to
evaluate the efficacy of glatiramer acetate (GA), an
immuno-modulatory and potentially neuro-protective
substance which is in clinical use for the treatment of
relapsing remitting multiple sclerosis, for the prevention
of mortality from CM.
GA, also known as copolymer 1, is a heterogeneous mix of
polypeptides containing the four amino acids alanine,
lysine, glutamic acid and tyrosine in definite ratios but
with no uniform sequence with an average molecular
weight of 5,000–9,000 daltons [21]. GA was synthesized
to resemble the structure of myelin basic protein (MBP),
one of the major components involved in EAE and multi-
ple sclerosis but instead of inducing the disease, it was
found to be protective [22]. GA was approved by the FDA
for the treatment of relapsing remitting multiple sclerosis
in 1996. GA has been shown to be of benefit in different
experimental diseases models as amyotrophic lateral scle-
rosis (ALS) [23], Alzheimer disease [24] and experimental
colitis [25]. In addition, GA exerts beneficial effects on
neuronal degeneration after facial nerve axonotomy [23],
graft rejection and graft versus host disease [26,27].
Recently murine HIV-1 encephalitis [28] was successfully
ameliorated by GA treatment. These promising results
warrant the evaluation of this drug in experimental CM.
Methods
Animals and treatment
A total of 72 six to eight weeks old C57BL/6J mice
(Charles River, Sulzfeld, Germany) were used for this
study during four subsequent experimental infections. 68
animals were infected intraperitoneally with 1 × 106 para-
sitized red blood cells of a homologue donor, which had
been infected with frozen polyclonal stocks of P. berghei
ANKA. Four animals were used as non-infected control
animals. The clinical severity of the disease was assessed
by the SHIRPA-score primary screen on baseline, day 5
post-infection and before death [29]. The primary screen
comprises a battery of 40 simple tests for evaluating neu-
romuscular, spinocerebellar, sensory, neuropsychiatric
and autonomic functions in mice by observational assess-
ment. The scoring starts with the evaluation of undis-
turbed behaviour in the viewing jar. Subsequently, motor
behaviour is observed and a sequence of manipulations
using tail suspension is performed and visual acuity, grip
strength, body tone and reflexes are recorded. Finally,
autonomous functions like skin color and heart rate are
assessed followed by measurement of core body tempera-
ture. The values of the respective tests were then summed
up and the cumulative SHIRPA-score was calculated as
described previously [29]. Healthy mice show a value of
about 30 while moribund CM animals show values of
about 10.
From the day of infection, animals of the treatment group
(n = 34) were injected subcutaneously daily with 100 μl
Copaxone (20 mg/ml GA, Sanofi-Aventis, Frankfurt, Ger-
many) after anesthesia with Forane (Abbott Laboratories,
Queensborough, UK) for two minutes on alternating
injection sites. The control group (n = 34) was injected the
same amount of saline (Fresenius Kabi, Graz, Austria).
The course of infection was closely monitored. Core body
temperature and weight were assessed daily. Parasitaemia
was monitored daily by thin blood smear from tail blood.
At day 4 post-infection 16 infected animals were killed to
study the early course of the disease. Between day 6 and
day 9 post-infection 37 of the infected mice developed
signs of CM and were killed for ethical reasons as soon as
their body temperature dropped to 30°C, a valid marker
for imminent death [29]. Mice which did not develop cer-
ebral malaria were killed on day 11 post-infection to min-
imize suffering, as it is well established that animals
which do not develop CM until day 10 post-infection will
die from overwhelming parasitaemia about three weeks
after infection. All animals were given a lethal dose of 0.5
ml (25 mg/ml) thiopental (Biochemie, Kundl, Austria)
intraperitoneally. Deeply anesthetized mice were transcar-
dially perfused with ice-cold phosphate buffered saline
(PBS) for two minutes followed by ice-cold fixative solu-
tion for 15 min with a pressure controlled syringe pump
(Fresenius-Kabi, Germany). Animal studies conformed to
the Austrian guidelines for the care and use of laboratory
animals and were approved by the Austrian Government.
Western blot
Animals (total n = 38, treatment = 19, control = 19) were
perfused with PBS for two minutes. Samples of the fore-
brain and brain stem with cerebellum were processed sep-
arately as described previously [30]. The microdissected
tissue was homogenized in ice-cold buffer (pH 7.5) con-
taining 50 mM Tris-Cl, 5 mM EDTA, 50 mM NaCl, 5 mMMalaria Journal 2009, 8:36 http://www.malariajournal.com/content/8/1/36
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DTT, 0.1% Np-40, 50 mM NaF, 1 mM PMSF, 1 mM
Na3VO4 plus a protease inhibitor cocktail (Roche, Man-
nheim, Germany) and centrifuged at 18,500 g for 20 min
at 4°C. Protein balanced samples were analysed using
standard techniques. The bottom parts of the blots were
probed with a monoclonal antibody directed against
cleaved caspase-3 (Cell Signaling, Danvers, MA, USA;
1:1,000 in blocking solution) overnight at 4°C. To con-
trol and correct for equal loading, the top part of each blot
was probed for alpha-tubulin (Sigma, 1:20,000 in block-
ing solution) overnight at 4°C. Antibody binding was vis-
ualized using enhanced chemoluminescence reagents
(Lumiglo™; Cell Signaling).
Immunohistochemistry
After perfusion with 4% PFA in PBS, brains (total n = 30,
treatment = 15, control = 15) were postfixed for six hours
and cryoprotected with 30% sucrose in PBS. Frozen tis-
sues were cut into 20 μm and 40 μm thick coronal sec-
tions on a freezing cryotome (Leica Microsystems,
Nussloch, Germany). 20 μm thick sections were mounted
on Superfrost Plus slides (Microm International, Wall-
dorf, Germany) and air-dried. 40 μm thick sections were
kept in assorter buffer and stored at 4°C. The directly
mounted slides were stained with haematoxylin-eosin
(H&E) according to standard protocols and used for anal-
ysis of haemorrhagic brain area. 40 μm free-floating sec-
tions were blocked for endogenous peroxidase activity
(20% methanol containing 1% H2O2) for 30 min and
non-specific binding in blocking solution (20% normal
goat serum, 20% bovine serum albumin in Tris-buffered
saline containing 0.1% Triton X-100) for 1 hour at room
temperature. All antibodies were diluted in blocking solu-
tion. Rabbit monoclonal antibody against activated cas-
pase-3 (Cell Signaling) was diluted 1:1,000 and permitted
to bind overnight at 4°C. Biotinylated goat anti-rabbit
antibody (Vector Laboratories, Burlingame, CA, USA) was
then applied at a dilution of 1:200 for 1 h at room temper-
ature. Antibody binding was visualized using Vectastain
ABC kit (Vector Laboratories) and diaminobenzidine as
chromogen according to the manufacturer brochure and
counterstained with haematoxylin. Sections without pri-
mary antibody or with primary antibody preincubated
with caspase-3 blocking peptide (Cell Signaling) were
equally processed to control for unspecific binding.
Morphometric analysis
For morphometric analysis anatomical regions of interest
(ROI) at +2, -6 ± 350 μm bregma were determined as pre-
viously described [29]. Stereology was applied using a
computer-assisted image analysis system: Nikon E-800
microscope with a motorized stage and Stereo Investiga-
tor Software (MicroBrightField, Magdeburg, Germany).
The area fraction fractionator method which is based on
Cavalieri's principle was used to determine the section
area and the area of haemorrhage within [31]. One sec-
tion per ROI from each animal was examined systemati-
cally in a blinded way: the contour of the tissue was traced
with objective ×2, analysis was performed with objective
×40 with a counting frame of 500 × 300 μm and a sam-
pling grid area of 1,000 × 600 μm. The optical fractionator
stereological method was used to count brain sequestered
leukocytes and parenchymal cells immunopositive for
activated caspase-3 [31]. One section per ROI from each
animal was examined in a blinded way with objective
×100 with a counting frame of 70 × 50 μm and a sampling
grid area of 700 × 500 μm. As brain parenchymal cells,
only extravascular cells with a clear staining and morpho-
logical characteristics of neurons or glia were counted.
Cytokine determination
Mouse serum was harvested immediately before per-
fusion by puncture of the right cardiac ventricle. Five dif-
ferent cytokines (TNF-alpha, IFN-gamma, IL-2, IL-4, IL-5)
were measured simultaneously by a commercially availa-
ble cytometric bead array according to the manufacturers
protocol by FACS (BD Bioscience, San Jose, CA, USA).
Statistical analysis
To test for differences in survival Kaplan-Meier curves
were drawn and the treatment groups were compared
using Log-rank test. Parasitaemia levels and the cumula-
tive SHIRPA score were compared between treatment
groups by repeated measures ANOVA. The relative haem-
orrhagic brain area, brain sequestered leukocytes and cas-
pase-3 immunopositive brain parenchymal cells were
compared between treatment groups by Wilcoxon rank
sum test. Cytokine levels were compared by two-way
ANOVA with time point of sampling and treatment as fac-
tors. P-values were Bonferroni-corrected for multiple
comparisons. The values of IFN-gamma were logarithmi-
cally transformed to get equal variances. Calculations
were done using Insightful S-Plus 6.2 (Insightful Corpora-
tion, Seattle, WA, USA), graphs were drawn by GraphPad
Prism version 5.00 (GraphPad Software, San Diego, CA,
USA).
Results
GA treated animals have a lower risk for developing CM
Of the 68 infected animals 16 were killed on day 4 post-
infection in order to study alterations in the early course
of the disease. The remaining 52 animals entered the sur-
vival analysis. 37 of these mice developed signs of CM and
were killed between day 5 and 9 post-infection when
showing clinical signs of inevitable death (day 5, n = 6;
day 6, n = 23; day 7, n = 3; day 8, n = 1; day 9, n = 4). The
other 15 animals survived this critical period and were
killed on day 11 post-infection. 15 animals (57.7%) in the
treatment group developed CM compared to 22 animals
(84.6%) in the control group. Kaplan Meier curves areMalaria Journal 2009, 8:36 http://www.malariajournal.com/content/8/1/36
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shown in Figure 1. Log-rank test yielded a statistically sig-
nificant lower risk for developing CM in the treatment
group compared to the control group (p < 0.05).
GA treatment does not affect the clinical course of the 
disease or parasitaemia levels
In order to assess putative differences in the clinical course
of the disease, the SHIRPA score was performed on base-
line, day 5, in moribund CM animals and on day 11 post-
infection in animals which did not develop CM (NCM
group). No significant differences were found in the
respective values of the SHIRPA score between GA and
vehicle treated animals (Figure 2A). There was a trend
towards a higher/better SHIRPA score in GA treated NCM
animals on day 11 post-infection (p = 0.056; Figure 2A).
Parasitaemia levels were also compared and did not yield
significant differences (Figure 2B).
GA treatment does not result in reduction of 
microhaemorrhages or brain parenchymal apoptosis
In order to reveal putative effects of GA treatment on the
neuropathology of CM, conventional H&E staining,
immunohistochemistry and western blot analysis for acti-
vated caspase-3 was performed. Qualitative inspection of
H&E stained sections did not reveal differences between
GA and vehicle treated animals. All moribund CM ani-
mals showed the typical neuropathology of CM (i.e.
haemorrhage, sequestration, perivascular oedema). In the
early course of the disease (on day 4 post-infection) and
in infected animals without CM (NCM animals, 11 days
post-infection) no signs of microhaemorrhages were
observed.
Histopathological changes were quantified by stereologi-
cal methods. In moribund CM animals the relative haem-
orrhagic brain area was not significantly different between
GA and vehicle treated animals (Figure 3A). The relative
number of activated caspase-3 immunopositive brain
parenchymal cells on day 4 post-infection and in mori-
bund CM animals was not significantly different between
GA and vehicle-treated animals (Figure 3B). On day 11
post-infection no activated caspase-3 immunopositive
cells could be observed. Densitometric analysis of West-
ern blots did not show significant difference for activated
caspase-3 between GA and vehicle treated mice on day 4
post-infection or in moribund animals.
The relative number of brain sequestered leukocytes on
day 4 post-infection was not significantly different
between GA and vehicle-treated animals (Figure 3C). In
moribund animals GA treated animals showed a signifi-
cantly lower number of brain-sequestered leukocytes.
GA treated animals show lower IFN-gamma levels in the 
early disease course
The immuno-phenotype of animals was determined on
day 4, in moribund CM animals, and on day 11 post
infection in NCM animals by measuring 5 different
cytokines in sera. On day 4 post-infection GA treated ani-
mals showed a significantly lower level of IFN-gamma (p
< 0.05, Figure 4A). There were no significant differences in
the levels of IL-2, IL-4, IL-5 or TNF-alpha (Figure 4B, C, D,
E) between the treatment groups. IFN-gamma levels on
day 4 were significantly higher than the levels in mori-
bund animals or in animals on day 11 post-infection (Fig-
ure 4A, p < 0.001, Bonferroni corrected). TNF-alpha levels
on day 4 and in moribund animals were significantly
lower than on day 11 post-infection (Figure 4E, p < 0.001,
Bonferroni corrected). IL-2, IL-4, IL-5 levels on day 4 were
significantly lower than the levels in moribund animals or
in animals on day 11 post-infection (Figure 4B, C, D, p <
0.001, Bonferroni corrected). IL-5 levels in moribund ani-
mals were significantly lower than in animals on day 11
post infection (Figure 4D, p < 0.001, Bonferroni cor-
rected).
Discussion
The current study was conducted to evaluate the efficacy
of the immuno-modulatory agent GA in preventing the
death of C57Bl/6J mice infected with P. berghei ANKA due
to CM. A statistically significant lower risk for developing
CM in GA treated animals could be demonstrated. The
drug had no effect on the course of parasitaemia. The
mechanism of action seems to be an immuno-modula-
tory effect since lower IFN-gamma levels were observed in
GA-treated animals in the early course of the disease
which also led to a lower number of brain sequestered
leukocytes in treated animals. No direct neuro-protective
effect such as inhibition of caspase-3 mediated apoptosis
or reduction of microbleedings in the brain was observed.
Survival curves Figure 1
Survival curves. Kaplan-Meier curves for GA (circles) and 
vehicle (boxes) treated animals. Log-rank test yielded a sta-
tistically significant difference in the survival curves (p < 
0.05).
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Clinical course of the disease and parasitaemia levels Figure 2
Clinical course of the disease and parasitaemia levels. A: Cumulative SHIRPA score of GA (open bars) and vehicle 
(filled bars) treated animals on day 0, 5, 11 post-infection and in moribund animals with CM. B: Course of parasitaemia of GA 
(open bars) and vehicle (filled bars) treated animals. No significant differences were found in the respective values of the 
SHIRPA score and parasitaemia between GA and vehicle treated animals. Mean values and SEM are shown.
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Histological analysis of microhaemorrhages, activated caspase-3 positive cells and brain sequestered leukocytes Figure 3
Histological analysis of microhaemorrhages, activated caspase-3 positive cells and brain sequestered leuko-
cytes. Stereological analysis of histology of GA (open bars) and vehicle (filled bars) treated animals. A: Relative of microhaem-
orrhages affected brain area in moribund CM animals. B: Total number of parenchymal cells immunopositive for activated 
caspase-3 on day 4 post-infection and in moribund CM animals. C: Total number of brain sequestered leukocytes on day 4 
post-infection and in moribund CM animals. Mean values and SEM are shown.
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GA is able to bind to MHC class 2 molecules on antigen
presenting cells and competes with myelin basic proteins
(MBP) and other myelin associated antigens such as pro-
teolipid protein (PLP) and myelin-oligodendrocyte glyco-
protein (MOG) for this binding or even displaces proteins
from the binding site [32]. This mechanism reduces the
ability of MBP/MHC complexes to bind to and activate
myelin reactive T-cells [33]. Importantly, dendritic cells
have recently been shown to be tightly involved in the
induction of murine CM [34].
Cytokine levels in sera Figure 4
Cytokine levels in sera. Cytokine levels in sera at day 4, 11 post-infection and in moribund animals with CM (pg/ml). (A: 
Interferon-gamma, B: Interleukin-2, C: Interleukin-4, D: Interleukin-5, E: Tumor-necrosis factor-alpha). On day 4 post-infection 
GA treated animals showed a significantly lower level of IFN-gamma than vehicle treated animals (A; *, p < 0.05). IFN-gamma 
levels on day 4 were significantly higher than the levels in moribund animals or in animals on day 11 post-infection (A; p < 
0.001). TNF-alpha levels on day 4 and in moribund animals were significantly lower than on day 11 post-infection (E; p < 0.001). 
IL-2, IL-4, IL-5 levels on day 4 were significantly lower than the levels in moribund animals or in animals on day 11 post-infec-
tion (B-D; p < 0.001). IL-5 levels in moribund animals were significantly lower than in animals on day 11 post-infection (D; p < 
0.001). Mean values and SEM are shown.
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Sequestered leukocytes are recognized to be causally
related to the pathogenesis of murine CM. The onset of
neurological signs and symptoms is paralleled by the
sequestration of CD8+ T-lymphocytes in the brain, and
depletion of these cells confers protection against CM.
Accumulation of activated T cells in the brains of CM mice
has been shown by different experimental approaches
[5,35]. Beside T-lymphocytes, monocytes are the major
cell population sequestering on the murine cerebral
endothelium in fatal CM [36]. Exposure of monocytes to
GA inhibits their activation by pro-inflammatory
cytokines (in particular by IFN-gamma) in vivo and in
vitro [37]. Further, IFN-gamma release is suppressed by
GA treatment [38,39]. IFN-gamma has recently been iden-
tified to be a critical cytokine in the pathogenesis of
murine CM [6,40]. Hence, the decreased IFN-gamma lev-
els on day 4 post-infection in treated animals in addition
to a relative IFN-gamma resistance of brain sequestered
monocytes could be the mechanism of action conferring
protection from CM in our mouse model. Indeed, in the
current study, a lower number of brain sequestered leuko-
cytes was observed in CM animals treated with GA.
Whereas no subtype characterization of brain sequestered
leukocytes was achieved in the study presented, this
important issue is currently under investigation in our
laboratory to further elaborate the exact mechanisms of
GA mediated protection from murine CM. Nevertheless,
the data presented here, besides uncovering a potential
adjunctive treatment, allow new insights into the
immuno-pathogenesis of experimental CM.
The neuro-protective effects of GA have been demon-
strated in several animal studies. In the EAE model and in
an optic-nerve injury model GA protected neurons from
demyelination, axonal damage and degeneration [41,42].
Further, anti-apoptotic effects have been reported for GA
[43]. In a rat model for elevated intraocular pressure,
apoptosis of retinal ganglion cells was reduced by GA. In
the current study apoptosis was investigated by immunos-
taining of activated caspase-3 in brain sections and brain
homogenates. No significant differences were observed
between the two treatment groups. Therefore, the protec-
tive effect of GA is most likely not mediated by inhibition
of caspase-3 induced apoptosis. Noteworthy, in a recent
study administration of EPO protected mice from death of
CM and the effect of EPO was also not related to the inhi-
bition of apoptosis [44]. However also conflicting data on
the effect of EPO on neuronal apoptosis is existing [45]. In
previous studies we demonstrated that neuronal apopto-
sis and the occurrence of parenchymal microhaemor-
rhages are mainly features of late murine cerebral malaria
[29,30]. In the present study, mice which developed clin-
ical signs of CM invariably died regardless of their treat-
ment status, showing the typical histopathological
hallmarks of murine CM. This is a further argument that
the effect of GA was rather immuno-modulation during
the early course of the disease and not neuro-protection
aiming at later stages of CM.
It should be noted that GA did neither change the course
of parasitaemia nor the clinical course of the disease. This
is of importance since a new adjunctive drug for treating
severe complicated malaria must not interfere with para-
site clearance through schizonticidal medication [46].
Further, clinical presentation was not affected in the early
course of the disease which can be regarded as an indica-
tor that GA administration is obviously well tolerated in
mice infected with P. berghei ANKA. In general, subcutane-
ous treatment with GA seldom causes severe side effects
[23]. The most frequent adverse events are local reactions
on the injection site [47]. No higher incidence of infec-
tions is reported, an issue which is critical with respect to
putative future studies in humans in view of concomitant
infections in malaria endemic areas [48].
Conclusion
In conclusion, the present pilot study provides direct evi-
dence that GA, a drug which has been safely administered
to patients with relapsing remitting multiple sclerosis for
several years, reduces the risk for experimental cerebral
malaria. The mechanism of action seems not to be neuro-
protection through inhibition of caspase-3 dependent
apoptosis or inhibition of parasite growth but rather
immuno-modulation in the early course of the disease.
Further studies are currently performed to evaluate the
exact mechanisms of GA mediated immuno-modulation
in CM and to determine the most effective dosing and
timing of treatment. The current findings support the
important role of the host immune response in the patho-
physiology of murine CM and might lead to the develop-
ment of new adjunctive treatment strategies.
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